Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

NIH-funded research enhances genetic testing for health equity

NIH-funded research enhances genetic testing for health equity

Selection, optimization, and validation of genetic tests for 10 common diseases

Selection, optimization, and validation of genetic tests for 10 common diseases

What factors are associated with recent prostate-specific antigen screening in transgender women?

What factors are associated with recent prostate-specific antigen screening in transgender women?

Study demonstrates chemo-preventive properties of alpha-santalol against prostate cancer development

Study demonstrates chemo-preventive properties of alpha-santalol against prostate cancer development

Plant-based diet linked to less erectile dysfunction, urinary incontinence in prostate cancer patients

Plant-based diet linked to less erectile dysfunction, urinary incontinence in prostate cancer patients

Representation matters to Black patients seeking prostate cancer information online, study shows

Representation matters to Black patients seeking prostate cancer information online, study shows

Rucaparib and its major metabolite exhibit differential biological activity and synergy

Rucaparib and its major metabolite exhibit differential biological activity and synergy

Wayne State researchers secure $1.4 million DoD grant for prostate cancer study

Wayne State researchers secure $1.4 million DoD grant for prostate cancer study

Reducing unnecessary testing or treatments in older patients

Reducing unnecessary testing or treatments in older patients

New prostate cancer resource helps to better understand treatment options and outcomes

New prostate cancer resource helps to better understand treatment options and outcomes

Boosting fitness levels linked to lower prostate cancer risk

Boosting fitness levels linked to lower prostate cancer risk

Protein may hold key to restoring treatment response in drug-resistant neuroendocrine prostate cancer

Protein may hold key to restoring treatment response in drug-resistant neuroendocrine prostate cancer

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Long-term prostate cancer treatment study informs decisions for diverse groups

Long-term prostate cancer treatment study informs decisions for diverse groups

Team approach to prostate cancer: PCPs and urologists offer hope with active surveillance

Team approach to prostate cancer: PCPs and urologists offer hope with active surveillance

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Study evaluates factors associated with selection of active surveillance for low-risk prostate cancer

Study evaluates factors associated with selection of active surveillance for low-risk prostate cancer